Panacea HAAH Blood Test

Panacea HAAH Blood Test is a blood test that works by measuring the serum levels of Human Aspartyl (Asparaginyl) -Hydroxylase (HAAH) (1). This test is recommended for men and women, 50 years of age or older, who have smoked cigarettes extensively in the past, regardless of whether they currently smoke 5, 6, 9. HAAH levels in the serum of individuals with lung cancer are three-fold higher when compared to individuals who are cancer-free 6, 3, 9.

Panacea HAAH Blood Test provides useful information about the likelihood of lung cancer in those at highest risk, such as current or former smokers 6, 3.

The test also provides diagnostic information about lung cancer by measuring the level of HAAH in serum. Patients who have early stages of lung cancer, the only curable stages, as well as later stages, have higher serum HAAH levels than people without lung cancer 6, 9.

An elevated level of serum HAAH in a patient who has a higher than normal risk for lung cancer should indicate to the physician that further diagnostic evaluations may be useful to determine whether lung cancer is present. 6,3,9

Panacea HAAH Blood Test is a very helpful tool for physicians as it is more sensitive, specific, cost-effective, and practical than other proposed initial blood tests.

HAAH levels are significantly elevated in people with colorectal cancer compared to levels in cancer-free individuals 13. -. HAAH levels are elevated in the serum of individuals with stage I, II, III and IV colorectal cancer but not in the serum of most who are known not to have cancer 13.

Panacea HAAH Blood Test can help the early diagnosis of prostate cancer, too. It is a sensitive and specific test to improve current screening methods and to provide information about the probability of prostate cancer in men with PSA values < 4 ng/mL.  Men with prostate cancer have higher serum HAAH levels than men without prostate cancer.5, 7, 10, 12   

Panacea HAAH Blood Test provides the physician with additional information about the likelihood that a man with an abnormally high PSA value (PSA > 4ng/mL), with or without an abnormal DRE, may have prostate cancer 12, 10, 5, 7. It is helpful, therefore, to the physician to determine the need for prostate biopsy in such patients. Importantly, high serum HAAH levels are also seen in men who have normal PSA values (PSA < 4ng/mL) and normal DREs; prostate cancer is often not diagnosed in this population despite the facts that it is fairly common and often pathologically high-grade. A high serum HAAH level demonstrated by Panacea, in this often under-diagnosed population, should alert the physician to consider biopsy 10, 7.

Panacea HAAH Blood Test provides information to differentiate prostate cancer from benign conditions and to help guide patient management. Low levels of HAAH as seen in normal individuals, suggest a lower risk of cancer. The test is to be used in conjunction with PSA and DRE to help determine the likelihood that a patient has prostate cancer.10 

Panacea HAAH Blood Test is a blood test which aids to detect the recurrence of breast cancer 7. The test provides useful diagnostic information about breast cancer by measuring the level of HAAH in serum 7, 18. Serum HAAH levels are significantly elevated in women with breast cancer compared to levels in cancer-free women.4, 8, 11, 12

In addition, HAAH levels are elevated in the serum of women with stage I, II, III and IV breast cancer but not in the serum of most patients in complete remission.4, 8, 11, 12

Why use Panacea HAAH Blood Test?

Affordable

Rapid results

Compliance better than having screening done in radiology

May be repeated frequently

Only a physician can order Panacea HAAH Blood Test. The results should be interpreted by a physician in the context of the patient’s medical, and family history and in the context of the patient’s physical findings and other laboratory results. Biopsy is necessary for a definitive diagnosis of most of the cancers.

1-. H. Yang, K. Song, T. Xue, X.P. Xue, T. Huyan, W. Wang and H. Wang “The distribution and expression profiles of human Aspartyl/Asparaginyl beta-hydroxylase in tumor cell lines and human tissues.” Oncology Reports, 24, 1257-1264, 2010.

2-. Lebowitz, M.L., Otahalova, E., Ghanbari, H.A. “A Novel Biomarker to Diagnose and Monitor Acute Myelogenous Leukemia.” 1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development,

Chicago, IL (2006)

3-. Nedim Ince, Suzanne de la Monte, Jack R. Wands. “Overexpression of Human Aspartyl (Asparaginyl) β-Hydroxylase  is associated with malignant transformation.” Cancer Research: 60, 1261-1266, 2000.

4-. H. Ghanbari, M. Moshiri ,*, M. S. Lebowitz , S. F. Roberts , A. Zokaei-Ashtiani, C. J. Panchal, “HAAH-BASED MONITORING OF CANCER REMISSION/RECURRENCE, World Cancer Congress,UICC, Montreal, ON, Canada, (2012).

5-. S.N. Keith, P.J. Harris, A.F. Repoli, M. Semenuk, H.A. Ghanbari and M.S. Lebowitz. The Serum Biomarker HAAH Identifies Prostate Cancer In Individuals With Low PSA Values. 2008 Genitourinary Cancers Symposium. San Francisco, CA. (2008)

6-. D. Khayat, R. Mouawad, M. S. Lebowitz, and H. A. Ghanbari. “Serum HAAH Level in NSCLC is a Diagnostic and Could be a Predictive Factor of Clinical Response.” 44th ASCO Annual Meeting, Chicago, IL (2008).

7-. S.N. Keith, P.J. Harris, A.F. Repoli, M. Semenuk, H.A. Ghanbari, and M.S. Lebowitz. " The Serum HAAH identifies Prostate Cancer in individuals with low PSA values". 2008 Genitourinary Cancer Symposium, February 2008, San Francisco

8-. Ghanbari, HA; Repoli, AF; Semenuk, M; Harris, PJ; Lebowitz, MS. HAAH as a Serum Biomarker for Breast Cancer. An AACR Special Conference in Cancer Research?Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Diego, CA (2007)

9-. Semenuk, M; Repoli, AF; Lebowitz, MS; Harris, PJ; Ghanbari, HA. HAAH is a Serum Biomarker for Lung Cancer. The Second Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment, Atlanta, GA (2007)

10-. Ghanbari, H.A., Vasauskas, A.A., Bensmail, I., Lebowitz, M.L. “HAAH is a Serum Biomarker for Prostate Cancer.” 1st  AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006)

11-. Vasauskas, A.A., Glass, L., Ghanbari, K., Lebowitz, M.L., Ranji, C., Maric, M., and Ghanbari, H.A.: “HAAH as a Biomarker for Pancreatic Adenocarcinoma Using IHC, qRT-PCR and ELISA.” AACR—Molecular Targets and Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA. 

12-. Audrey A. Vasauskas, Cyra M. Ranji, Kasra Ghanbari, Michael S. Lebowitz, and Hossein A. Ghanbari. Human Aspartyl (Asparaginyl) β-Hydroxylase is a Serum Biomarker of Breast, Ovarian, and Prostate Cancer. AACR 94th Annual  Meeting, July 11-14 2003, Washington, DC.

13. H.A. Ghanbari, A.F. Repoli, M. Semenuk, P.J. Harris and M.S. Lebowitz. HAAH as a serum biomarker for colorectal Cancer. An AACR Special Conference in Cancer Research?Advances in Colon Cancer Research Cambridge, MA (2007)